Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DME3BJL)

Drug Name

PF-07062119 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylyl cyclase C (GUCY2C)	TTLDPRG	GUC2C_HUMAN	Inhibitor	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Guanylyl cyclase C (GUCY2C)	DTT	GUCY2C	4.542	7.698	3.797	7.565

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Guanylyl cyclase C (GUCY2C)	DTT	GUCY2C	9.52E-03	2.35	5.13

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health.
2	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.